Klotho-derived peptide 1

Synonyms: KP1 (human)
Klotho-derived peptide 1 (KP1 (human)) 是一种具有衰老抑制、肾脏保护等多种活性的多肽,可与 TβR2 和 ATAD3A 结合,其与人 TβR2 结合的 Kd 值为 1.41 μM,与 ATAD3A 结合的 Kd 值为 0.319 μM;它通过结合 TβR2 阻断 TGF-β/Smad3 及下游 TGF-β 信号通路,抑制 miR-223-3p 表达并诱导 lncRNA-TUG1 表达,在转录后水平恢复内源性 Klotho,抑制细胞衰老标志物、成纤维细胞活化及肾小管上皮细胞凋亡,阻断细胞色素 c 释放和半胱天冬酶激活,维持线粒体超微结构完整并恢复线粒体蛋白水平;此外,它可通过内吞作用进入肾小管上皮细胞,抵御肾毒性损伤和缺氧损伤,重现全长 Klotho 的肾脏保护及抗纤维化作用,可用于慢性肾脏病、SARS-CoV-2 相关急性肾损伤等肾脏疾病相关研究。
Klotho-derived peptide 1
产品编号: MS-J54623 分子式: C149H203N39O43 分子量: 3228.44
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Klotho-derived peptide 1 (KP1 (human)) 是一种具有衰老抑制、肾脏保护等多种活性的多肽,可与 TβR2 和 ATAD3A 结合,其与人 TβR2 结合的 Kd 值为 1.41 μM,与 ATAD3A 结合的 Kd 值为 0.319 μM;它通过结合 TβR2 阻断 TGF-β/Smad3 及下游 TGF-β 信号通路,抑制 miR-223-3p 表达并诱导 lncRNA-TUG1 表达,在转录后水平恢复内源性 Klotho,抑制细胞衰老标志物、成纤维细胞活化及肾小管上皮细胞凋亡,阻断细胞色素 c 释放和半胱天冬酶激活,维持线粒体超微结构完整并恢复线粒体蛋白水平;此外,它可通过内吞作用进入肾小管上皮细胞,抵御肾毒性损伤和缺氧损伤,重现全长 Klotho 的肾脏保护及抗纤维化作用,可用于慢性肾脏病、SARS-CoV-2 相关急性肾损伤等肾脏疾病相关研究。

生物实验数据

生物活性 Klotho-derived peptide 1 (KP1 (human)) is a peptide with multiple activities including senescence inhibition and renal protection that binds to TβR2 and ATAD3A, with a Kd of 1.41 μM for binding to human TβR2 and a Kd of 0.319 μM for binding to ATAD3A; it binds TβR2 to block the TGF-β/Smad3 and downstream TGF-β signaling pathways, inhibits miR-223-3p expression, induces lncRNA-TUG1 expression, restores endogenous Klotho at the post-transcriptional level, suppresses cellular senescence markers, fibroblast activation, and renal tubular epithelial cell apoptosis, blocks cytochrome c release and caspase activation, maintains mitochondrial ultrastructural integrity, and restores mitochondrial protein levels; furthermore, it enters renal tubular epithelial cells via endocytosis, protects against nephrotoxic injury and hypoxic injury, recapitulates the renal protective and anti-fibrotic effects of full-length Klotho, and can be used for research related to renal diseases such as chronic kidney disease and SARS-CoV-2-associated acute kidney injury.
IC50 & Target

TGF-βR2

1.41 μM (Kd)

体外研究
(In Vitro)

Klotho-derived peptide 1 (KP1) 可通过转录后调控作用抑制 HK-2 细胞中 TGF-β1 诱导的细胞衰老,并恢复 mKlotho 和 sKlotho 蛋白的表达;可抑制 miR-223-3p,恢复 mKlotho、sKlotho 和 lncRNA-TUG1 的表达,并在 HK-2 细胞中抑制 miR-223-3p 诱导的细胞衰老及纤维化标志物表达。
Klotho-derived peptide 1 可抑制 TGF-β/Smad3/miR-223-3p 轴,恢复 mKlotho 与 sKlotho 的蛋白表达,并在 HK-2 细胞中拮抗 TGF-β1 诱导的细胞衰老与纤维化。
Klotho-derived peptide 1 可与重组人转化生长因子-β 受体 2 紧密结合,其平衡解离常数 (KD) 为 1.41 μM。
Klotho-derived peptide 1 可特异性结合重组人转化生长因子 β 受体 2;可与正常大鼠肾间质成纤维细胞 (NRK-49F) 裂解物中的内源性 TGF-β 受体 2 结合。
Klotho-derived peptide 1 可抑制 TGF-β1 诱导的肌成纤维细胞活化、细胞外基质蛋白表达以及经典和非经典 TGF-β 信号通路;可抑制 TGF-β1 诱导的细胞外基质蛋白的表达与 Smad2/3 磷酸化;可阻断 TGF-β1 与 TGF-β 受体 2 的结合、TGF-β 受体 1 与 TGF-β 受体 2 异二聚体的形成,以及可溶性 Klotho 与 TGF-β 受体 2 的相互作用。
Klotho-derived peptide 1 在采用 GFP-ATAD3A 转染裂解液的无细胞 MST 结合实验中,以高亲和力 (Kd = 3.19×10-7 M) 结合 ATAD3A;可在采用过表达 ATAD3A 裂解物的无细胞 DARTS 实验中,以剂量依赖方式稳定 ATAD3A。
Klotho-derived peptide 1 (3 μM; 1 h) 可恢复 HKC-8 肾小管上皮细胞中被 Cisplatin 降低的 ATAD3A 蛋白水平、HIGD2A 蛋白水平,并阻止细胞色素 c 从线粒体中释放。
Klotho-derived peptide 1 (10 μg/mL; 48 h) 可保护人肾近端小管 HK-2 细胞免受 SARS-CoV-2 N 蛋白诱导的损伤与凋亡,消除损伤及凋亡标志物的上调并降低凋亡细胞占比。
Klotho-derived peptide 1 (3 μM; 1 h) 可保护原代小鼠近端肾小管上皮细胞免受 Cisplatin (MS-E94993)、H/R 诱导的损伤、凋亡及线粒体功能障碍。

Western Blot Analysis

Cell Line: human kidney proximal tubular cells (HK-2)
Concentration: 10 μg/mL
Incubation Time: 48 h
Result: Abolished the SARS-CoV-2 N protein-induced upregulation of kidney injury molecule-1 (KIM-1), cleaved poly-ADP-ribose polymerase (PARP), p53, and FAS-associated protein with death domain (FADD).
Negated the increase in TUNEL-positive apoptotic cells induced by N protein, with efficacy comparable to recombinant human Klotho.

Western Blot Analysis

Cell Line: HKC-8 human renal tubular epithelial cells (Cisplatin-induced injury model and hypoxia/reoxygenation [H/R]-induced injury model)
Concentration: 3 μM (KP1); 7 μg/mL (Cisplatin)
Incubation Time: 1 h (KP1 pre-incubation); 24 h (cisplatin incubation)
1 h (KP1 pre-incubation); 24 h (hypoxia); 4-6 h (reoxygenation)
Result: Completely restored cisplatin-depleted ATAD3A protein levels in HKC-8 cells.\nRestored cisplatin-depleted HIGD2A protein levels and reversed cytochrome c translocation from mitochondria to cytosol in HKC-8 cells.
Completely restored H/R-depleted ATAD3A protein levels in HKC-8 cells. Restored H/R-depleted HIGD2A protein levels and reversed cytochrome c translocation from mitochondria to cytosol in HKC-8 cells.
体内研究
(In Vivo)

Klotho-derived peptide 1 (KP1) (1 mg/kg/天;静脉注射;每日给药;术后第 1 天开始,持续 6 天) 可通过恢复 mKlotho 和 sKlotho 蛋白表达、且不改变 Klotho mRNA 水平,抑制 UUO 诱导的慢性肾脏病中的细胞衰老与肾纤维化。
Klotho-derived peptide 1 (1 mg/kg/天;静脉注射;每日;术后第 4 天开始,持续 7 天) 可通过抑制 miR-223-3p,在 UIRI 诱导的慢性肾脏病模型中抑制细胞衰老、恢复 Klotho 蛋白表达、改善肾功能并抑制纤维化。
Klotho-derived peptide 1 (1 mg/kg/天;静脉注射;术后第 1 天开始每日给药) 可通过恢复 lncRNA-TUG1 和 Klotho 蛋白的表达、抑制 miR-223-3p,减轻 UUO 诱导的慢性肾脏病中 shTUG1 介导的肾损伤。
Klotho-derived peptide 1 (1 mg/kg/天;静脉注射;术后第 4 天开始每日给药) 可逆转由 miR-223-3p 诱导的 Klotho 表达下调、细胞衰老、纤维化及 UIRI 诱导的慢性肾脏病中的肾功能损伤。
Klotho-derived peptide 1 (1 mg/kg;静脉注射;每日 1 次;共 4 天) 可改善雄性 C57BL/6 小鼠中由 SARS-CoV-2 N 蛋白和缺血再灌注损伤诱导的急性肾损伤,血清肌酐与血尿素氮水平降低、Klotho 表达恢复、损伤标志物诱导受抑制以及肾小管凋亡被抑制可作为佐证。
Klotho-derived peptide 1 (1 mg/kg;静脉注射;每日给药;连续 7 天) 可在单侧缺血再灌注损伤的雄性 BALB/c 小鼠中维持肾功能,减少约 60% 的肾纤维化,抑制 TGF-β 信号通路,并恢复内源性 Klotho 的表达。
Klotho-derived peptide 1 (1 mg/kg;静脉注射;每日一次;连续 6 天) 可使单侧输尿管梗阻雄性 BALB/c 小鼠的肾纤维化程度降低约 50%,抑制 TGF-β 信号通路与肾脏炎症反应,并恢复内源性 Klotho 的表达。
Klotho-derived peptide 1 (KP1) (5 mg/kg;每日;顺铂给药前 2 天/缺血再灌注前 2 天) 可通过改善肾功能障碍、降低损伤标志物表达、减少肾小管凋亡及恢复线粒体蛋白水平,保护雄性 C57BL/6 小鼠免受顺铂诱导的急性肾损伤。

Animal Model: C57BL/6 (male, 8-10 weeks old, unilateral ureteral obstruction model)
Dosage: 1 mg/kg/day
Administration: i.v.; daily; 6 days starting day 1 post-surgery
Result: Abolished the induction of cellular senescence markers p21, p16, and γ-H2AX in kidney tissue.
Restored renal expression of membranous Klotho (mKlotho) and soluble Klotho (sKlotho) proteins, but did not affect Klotho mRNA levels.
Inhibited upregulation of fibrotic markers fibronectin, collagen I, and α-SMA in kidney tissue.
Animal Model: C57BL/6 (male, 8-10 weeks old, unilateral ischemia-reperfusion injury model)
Dosage: 1 mg/kg/day
Administration: i.v.; daily; 7 days starting day 4 post-surgery
Result: Eliminated tubular cellular senescence markers including p21, p16 and γ-H2AX as well as SA-β-Gal, recovered mKlotho and sKlotho protein abundance without altering Klotho transcription, lowered fibronectin, collagen I and α-SMA fibrotic markers, relieved renal dysfunction via declined serum creatinine and BUN, and inhibited UIRI-triggered renal miR-223-3p overexpression.
Animal Model: C57BL/6 (male, 8-10 weeks old, unilateral ureteral obstruction model)
Dosage: 1 mg/kg/day (Klotho-derived peptide 1); 2.5 mg/kg (shTUG1 plasmid)
Administration: i.v.; daily starting day 1 post-surgery (Klotho-derived peptide 1); i.v.; single dose day 1 post-surgery (shTUG1 plasmid)
Result: Recovered shTUG1-suppressed renal lncRNA-TUG1 expression, restrained shTUG1-evoked renal miR-223-3p elevation, restored shTUG1-depleted mKlotho and sKlotho protein without changing Klotho mRNA, erased shTUG1-induced p21, p16 and γ-H2AX senescence markers, and suppressed shTUG1-triggered overexpression of fibronectin, collagen I and α-SMA fibrotic proteins.
Animal Model: C57BL/6 (male, 8-10 weeks old, unilateral ischemia-reperfusion injury model)
Dosage: 1 mg/kg/day (Klotho-derived peptide 1); 2.5 mg/kg (miR-223-3p overexpression plasmid)
Administration: i.v.; daily starting day 4 post-surgery (Klotho-derived peptide 1); i.v.; single dose day 4 post-surgery (miR-223-3p overexpression plasmid)
Result: Reduced the elevated renal miR-223-3p levels induced by the overexpression plasmid.
Restored mKlotho and sKlotho protein expression that was suppressed by miR-223-3p overexpression, without affecting Klotho mRNA levels.
Abolished the exacerbated induction of cellular senescence markers p16 and γ-H2AX caused by miR-223-3p overexpression.
Inhibited the increased expression of fibrotic markers fibronectin, collagen I, and α-SMA triggered by miR-223-3p overexpression.
Improved kidney function as measured by decreased serum creatinine and blood urea nitrogen levels.
Animal Model: BALB/c (male, 20-22 g, unilateral ischemia-reperfusion injury)
Dosage: 1 mg/kg
Administration: i.v.; daily; 7 consecutive days
Result: Selectively enriched in damaged kidney tissue with negligible deposition in healthy kidney and other visceral organs, and alleviated renal dysfunction by lowering serum creatinine and BUN concentrations.
Markedly shrank renal fibrotic lesions and diminished fibronectin/α-SMA positive interstitial regions, while decreasing profibrotic protein fibronectin, α-SMA and collagen expression in kidney tissues.
Interrupted TGF-β1/TβR2 signaling cascade via downregulating phosphorylated Smad, MAPK and TβR2 proteins, and rescued renal endogenous Klotho protein abundance.
Animal Model: BALB/c (male, 20-22 g, unilateral ureter obstruction)
Dosage: 1 mg/kg
Administration: i.v.; daily; 6 consecutive days
Result: Accumulated selectively in obstructed renal tissue (~12 ng/mg) with far lower distribution in normal kidney and visceral organs, and localized mainly to renal tubular epithelial cells. It cut renal fibrotic region and vimentin-positive cell numbers by roughly half.
Downregulated fibronectin, α-SMA and collagen I renal protein abundance by about 65%, 80% and 80%, disrupted TGF-β cascade by lowering phosphorylated Smad2/3, ERK/JNK/p38 and TβR2 protein levels.
Eliminated renal F4/80 macrophage marker, suppressed immune cell infiltration, and recovered renal Klotho protein expression and positive staining area to prominent levels.

化学信息

分子量 3228.44
分子式 C149H203N39O43
别名 KP1 (human)

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础